Key Points
- Personalis CEO Christopher Hall sold 100,000 shares on July 9 in a pre-arranged Rule 10b5-1 transaction at an average price of $15.08, totaling about $1.51 million.
- After the sale, Hall still owned 235,986 shares valued at roughly $3.56 million, representing a 29.76% reduction in his position.
- Personalis shares were trading up 3.8%, and the stock has surged to near its 52-week high of $15.36 as analysts maintain a Moderate Buy consensus with a $11.67 target price.
Personalis, Inc. (NASDAQ:PSNL - Get Free Report) CEO Christopher Hall sold 100,000 shares of the company's stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares of the company's stock, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Personalis Trading Up 3.8%
NASDAQ:PSNL opened at $14.65 on Friday. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -14.36 and a beta of 2.24. Personalis, Inc. has a 1-year low of $3.84 and a 1-year high of $15.36. The business's fifty day moving average price is $9.81 and its 200 day moving average price is $8.62.
Personalis (NASDAQ:PSNL - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to analysts' expectations of $14.48 million. Equities analysts forecast that Personalis, Inc. will post -1.06 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages have commented on PSNL. BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Monday, May 11th. Wall Street Zen cut shares of Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Personalis in a report on Tuesday, April 21st. Finally, Morgan Stanley raised their target price on shares of Personalis from $9.00 to $13.00 and gave the company an "equal weight" rating in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Personalis presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.
View Our Latest Research Report on PSNL
Hedge Funds Weigh In On Personalis
Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd raised its position in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after buying an additional 1,479 shares during the last quarter. Deutsche Bank AG grew its position in Personalis by 4.5% during the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company's stock worth $309,000 after buying an additional 1,655 shares in the last quarter. Royal Bank of Canada grew its position in Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after buying an additional 2,395 shares in the last quarter. Howland Capital Management LLC increased its stake in Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company's stock valued at $1,872,000 after acquiring an additional 2,500 shares during the period. Finally, Intech Investment Management LLC increased its stake in Personalis by 23.4% during the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company's stock valued at $162,000 after acquiring an additional 3,851 shares during the period. Institutional investors own 61.91% of the company's stock.
Personalis Company Profile
(
Get Free Report)
Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.
In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
